New hive drug LP-003 passes first safety check in healthy volunteers
NCT ID NCT06604949
First seen Jan 03, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-stage study tests a single dose of a new drug called LP-003 in 12 healthy adults to see if it is safe and how the body processes it. The drug is designed to help control chronic spontaneous urticaria (long-term hives). Participants are healthy volunteers aged 18 to 50. The study focuses on side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.